Global Pregabalin Market Insights Forecasts to 2033

• The Global Pregabalin Market Size was Valued at USD 1.65 Billion in 2023
• The Market Size is Growing at a CAGR of 2.82% from 2023 to 2033
• The Worldwide Pregabalin Market Size is Expected to Reach USD 2.18 Billion by 2033
• Asia-Pacific is expected to Grow the fastest during the forecast period

The Global Pregabalin Market Size is Anticipated to Exceed USD 2.18 Billion by 2033, Growing at a CAGR of 2.82% from 2023 to 2033.

Market Overview

Pregabalin is a drug that is primarily used to treat fibromyalgia, neuropathic pain, and some types of seizures. The class of pregabalin is anticonvulsants or antiepileptics. Pregabalin reduces the release of neurotransmitters in the transmission of pain signals by binding to calcium channels in the central nervous system. It is structurally bonded to gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, and has been modified to improve its diffusion across the blood-brain barrier. The pregabalin is administered orally and is available in capsules or oral solutions. Also, its absorption is independent of dose & it readily crosses the blood-brain barrier. The half-life of the pregabalin is 6.3 hrs. The high and growing prevalence of epilepsy and related illnesses, such as neuropathic pain and anxiety disorders, are likely to be the main growth factors for the pregabalin market, which is used in the management and treatment of these disorders. When administered before surgery, it relieves pain but also induces tiredness and visual abnormalities in epilepsy patients living in low- and middle-income countries during the early stages of the disease. The Pregabalin market is likely to be boosted by an increase in elderly people suffering from neuropathic diabetes, as well as the prevalence of diabetes, HIV, cancer, epilepsy, fibromyalgia, and other diseases.

Report Coverage

This research report categorizes the market for the global pregabalin market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global pregabalin market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global pregabalin market.

Driving Factors

The rising number of cases of epilepsy, neuropathic pain, and anxiety disorder are important factors to boost the pregabalin market growth during the forecast period. The increase in awareness of epilepsy and its treatment alternatives among the general population and healthcare professionals contributes to the pregabalin market prediction. The increased awareness of epilepsy contributes to a larger demand for epileptic medications, which adds to market growth. increasing the investment and surge in R&D activities for other applications has significantly expanded in emerging markets. The market growth is fueled by a focus on improving healthcare facilities and infrastructure are increasing partnerships between public and private players for funding and technology application. Pregabalin's effectiveness in managing pain and anxiety disorders in the elderly population is driving market growth due to its appeal to the growing global aging demographic. Hence, these factors are significantly increasing the growth of the global pregabalin market during the forecast period.

Restraining Factors

The pregabalin market faces challenges due to alternative medications, patent expiration, and stringent regulatory requirements, despite its growth prospects. Also, the severe side effects of pregabalin may limit its usage in some patient populations. Hence, these factors may hamper the market growth of the global pregabalin market during the forecast period.

Market Segmentation

The global pregabalin market share is classified into dosage forms, application, distribution channel, and end-users.

• The oral solution segment is expected to hold the largest share of the global pregabalin market during the forecast period.

Based on the dosage forms, the global pregabalin market is divided into oral capsule, oral solution, oral tablet, and extended release. Among these, the oral solution segment is expected to hold the largest share of the global coffee concentrate market during the forecast period. The segmental growth can be attributed to the control of some types of seizures. Oral solutions may have a faster beginning of effect than other dose forms, which can be useful for patients who seek immediate relief from symptoms.

• The neuropathic pain segment is expected to hold the largest share of the global pregabalin market during the forecast period.   

Based on the application, the global pregabalin market is divided into epilepsy, neuropathic pain, anxiety disorder, and others. Among these, the neuropathic pain segment is expected to hold the largest share of the global pregabalin market during the forecast period. The growth can be attributable to the increasing prevalence of diabetic neuropathy, and postherpetic neuralgia common contributes. Because of the high prevalence, a large patient population seeks relief from neuropathic pain symptoms, and it is effective.

• The retail pharmacy segment is expected to hold the largest share of the global pregabalin market during the forecast period.

Based on the distribution channel, the global pregabalin market is divided into hospital pharmacy, retail pharmacy, online pharmacy, and others. Among these, the retail pharmacy is expected to hold the largest share of the global pregabalin market during the forecast period. The segmental growth can be attributed to patients having easy access to retail pharmacies, making it convenient to get medication like pregabalin. Retail pharmacy have a large distribution network, with multiple locations throughout the neighborhood and community.

• The hospitals segment is expected to hold the largest share of the global pregabalin market during the forecast period.

Based on the end-users, the global pregabalin market is divided into hospitals, specialty clinics, homecare, and others. Among these, the hospitals are expected to hold the largest share of the global pregabalin market during the forecast period. The segmental growth can be attributed to the hospitals are equipped with specialist medical professionals and facilities to manage complex situations and give comprehensive care to patients suffering from diseases such as epilepsy, neuropathic pain, and anxiety disorders.

Regional Segment Analysis of the Global Pregabalin Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• Latin America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global pregabalin market over the predicted timeframe.

North America is anticipated to hold the largest share of the global pregabalin market over the predicted timeframe. The presence of significant important players is projected to dominate the market, and rising healthcare expenditure will drive the industry's development rate in this region. An increase in the number of R&D activities will accelerate the market's growth rate in this region. Chronic disease is becoming more common, and this development is being driven by well-established healthcare infrastructure, broad use of modern technology, and government initiatives to regulate the maintenance of health data.

Asia-Pacific is expected to grow at the fastest pace in the global pregabalin market during the forecast period. The development of healthcare infrastructure and an increasing geriatric population will boost the market's growth rate in this region. Asia-Pacific offers profitable opportunities for key players operating in the pregabalin market, thereby registering the fastest growth rate during the forecast period, owing to the developments in healthcare infrastructure, rise in R and D activities, as well as the well-established presence of domestic companies in the region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global pregabalin market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of overall competition within the market.

List of Key Companies

• Cipla
• Rising Pharmaceuticals
• Angels Pharma
• Zydus Group
• Viatris Inc.
• Amneal Pharmaceuticals LLC.
• Aurobindo Pharma
• Markans Pharma Ltd.
• Lupin Pharmaceuticals
• Glenmark Pharmaceuticals Limited
• Teva Pharmaceutical Industries Ltd.
• Sciegen Pharmaceuticals Inc.
• Novartis AG
• Torrent Pharmaceuticals Ltd.
• CTX Life Sciences
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2023, SinoT's ANDA application for pregabalin extended-release tablets 82.5 mg, 165 mg, and 330 mg for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN) has been approved by the food and drug administration.

• In April 2023, AGP Limited, a Pakistani pharmaceutical company, bought a select portfolio of goods from Viatris Inc., an American company, in April 2023. The portfolio comprises various antidepressants, including pregabalin, antihypertensive and ophthalmic drugs.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global pregabalin market based on the below-mentioned segments: 

Global Pregabalin Market, By Dosage Forms

• Oral Capsule
• Oral Solution
• Oral Tablet
• Extended Release

Global Pregabalin Market, By Application

• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Global Pregabalin Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pregabalin Market, By End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Pregabalin Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa